UroGen Pharma (URGN) Total Liabilities (2016 - 2026)

UroGen Pharma (URGN) has reported Total Liabilities for 11 consecutive years, with $377.9 million the latest figure, recorded in Q1 2026.

• Quarterly Total Liabilities rose 28.52% year-over-year to $377.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $377.9 million (up 28.52% YoY) and the FY2025 annual result came in at $305.9 million, up 3.88% from the prior year.
• Total Liabilities climbed to $377.9 million in Q1 2026 per URGN's latest filing, from $305.9 million in the prior quarter.
• Over the last five years, Total Liabilities for URGN reached as high as $377.9 million in Q1 2026 and fell as low as $182.8 million in Q1 2022.
• A 5-year average of $257.2 million and a median of $243.5 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities soared 773.63% — and 2025, when it increased 3.88%.
• Year by year, Total Liabilities stood at $225.0 million in 2022, then increased by 8.24% to $243.5 million in 2023, then grew by 20.94% to $294.5 million in 2024, then climbed by 3.88% to $305.9 million in 2025, then gained by 23.54% to $377.9 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $377.9 million, $305.9 million, and $300.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.